SLC5A2 and type 2 diabetes mellitus: Inhibitors of SGLT2 reduced the accumulation of Aβ in the cortical region of AD-T2DM mice (APP/PS1xdb/db mice) which is a genetically diabetic model of T2DM and showed the same effect on the amount of tau induced pathological cerebral atrophy (Wiciński et al., 2020).